Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766

Sorafenib in advanced hepatocellular carcinoma

Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628

Signatures of mutational processes in human cancer

Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660

Sorafenib in Advanced Hepatocellular Carcinoma

정, 재. (2008) · Cited by 5,586

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497

Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer

Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Breder, V. V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32453-9 · Cited by 3,725

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756

Correlation Between Treatment‐Related Adverse Events and Efficacy of Camrelizumab in Combination With Apatinib in Patients With Unresectable Hepatocellular Carcinoma

Zhang, T., Du, S., Zhang, Y., Liu, R., Li, J., Zhao, C., & Xu, J. (2025) · Cancer Medicine · doi:10.1002/cam4.70713 · Cited by 1

The evaluation of the efficacy and safety about apatinib combined with immune checkpoint inhibitors in advanced gastric cancer: a real-world study

Zhu, P.-F., Yang, L., & Chen, Z.-L. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1578011 · Cited by 1

Efficacy and safety analysis of transarterial chemoembolization combined with tyrosine kinase inhibitors and immune checkpoint inhibitors with or without microwave ablation for unresectable hepatocellular carcinoma: a retrospective, multicenter, case-control study

Wang, N., Xu, J., Zhan, C., Cao, P., Xue, T., Li, J., Wei, Z., & Ye, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1639515 · Cited by 1

Comparison of the Effectiveness of Transarterial Bland Embolization and Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: A Propensity Score Matched Study of 980 Patients

Zhang, H., Xu, J., Meng, H., & Shen, L. (2025) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2025.06.014 · Cited by 1

Combination therapy with toripalimab and lenvatinib in metastatic type 2 papillary renal cell carcinoma: a Case Report

Wang, W., Chen, M., Xue, W., & Zeng, D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1591489 · Cited by 1

Development and validation of a nomogram to predict surgical resection after conversion therapy in unresectable hepatocellular carcinoma

Su, Y., Liang, Y., Zhong, D., Chen, Y., Yan, H., Yang, Q., Wang, M., Leng, Z., & Huang, X. (2026) · European Journal of Radiology · doi:10.1016/j.ejrad.2026.112724 · Cited by 1

Subacute liver failure caused by immunotherapy in a patient with gastric cancer was improved after multimodal treatment with artificial liver combined with liver-protective drugs: a case report

Wang, Y., Wen, Y., Jiang, Y., Li, C., & Liu, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1755661 · Cited by 1

Impact of Age on Patient-Reported Outcomes with First-Line Camrelizumab plus Rivoceranib versus Sorafenib in Adults with Unresectable Hepatocellular Carcinoma: Post Hoc Analyses of the CARES-310 Open-Label, Randomized, Phase 3 Trial

Chan, S. L., Kaseb, A. O., Alexander, L., Meng, X., Ryan, K., Shi, W., & Vogel, A. (2026) · Liver Cancer · doi:10.1159/000551156 · Cited by 1

Neoadjuvant mFOLFOX6 plus camrelizumab and apatinib in colon cancer and biomarker research via spatiotemporal-omics profiling

Tong, Z., Gao, L., Wang, D., Zhao, P., Bao, X., Zhang, H., Dai, X., Liu, L., Zhu, X., Gao, Y., et al. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01387-0 · Cited by 1

[Clinical comment of programmed cell death protein 1 immunotherapy for advanced head and neck cancer].

Guo, W. (2020) · PubMed Central · doi:10.7518/hxkq.2020.05.003 · Cited by 1

Concurrent chemoradiotherapy improves prognosis and quality of life of patients with metastatic and recurrent hepatocellular carcinoma.

Sun, S., Shen, B., & Wang, N. (2023) · PubMed Central · Cited by 1

Development and validation of a ligand–receptor pairs signature to predict outcome and provide a therapeutic strategy in gastric cancer

Yang, W., Zhao, X., Duan, L., Niu, L., Zhang, Y., Zhou, W. J., Li, Y., Chen, J., Fan, A., Xie, Q., et al. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2219843 · Cited by 1

Treatment-related adverse events of combined anti-angiogenic and immune checkpoint inhibitors: systematic review and meta-analysis

Chen, L., Wu, L., Zhang, L., Huang, Q., & Huang, L. (2022) · Oncology and Translational Medicine · doi:10.1007/s10330-022-0605-5 · Cited by 1

Camrelizumab Combined with Apatinib for Portal Vein Tumor Thrombus in Advanced Hepatocellular Carcinoma: Two Case Reports

Chen, N., Zhang, L., Gao, A.-M., Piao, L., Quan, X., & Shen, X. (2024) · British Journal of Hospital Medicine · doi:10.12968/hmed.2024.0211 · Cited by 1

Combination of Anti–Programmed Death 1 Therapy and Apatinib for a Patient with Hepatocellular Carcinoma and Brain Metastasis: Case Report and Literature Review

Liu, Y., Hao, S., Ji, N., Wang, J., & Zhang, L. (2020) · World Neurosurgery · doi:10.1016/j.wneu.2020.06.015 · Cited by 1

Resection of “down-staged” advanced hepatocellular carcinoma after treatment with the VEGFR2 inhibitor apatinib: five cases report

Hou, Z., Zhu, K., Yang, X., Zhou, H., Chen, P., Yu, G., Zhu, X., Cui, Y., Song, T., Li, Q., et al. (2020) · Translational Cancer Research · doi:10.21037/tcr-19-3019 · Cited by 1

Combination treatment for advanced hepatocellular carcinoma with portal vein tumour thrombus: A case report

Wang, J., Wang, J., Wang, J., Qian, Z., Xu, W., & Hang, X. (2021) · Journal of International Medical Research · doi:10.1177/0300060521994406 · Cited by 1

Immunotherapy and targeted therapy converted radical surgery in an advanced hepatocellular carcinoma with tumor emboi of portal vein and hepatic vein

Huang, X., Zhang, X., Jiang, Y., & Hu, H. (2021) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2021.06.044 · Cited by 1

Effect of apatinib combined with chemotherapy on quality of life and related complications in patients with advanced gastric cancer

Hong, D., Wei, Y., Zang, A., Wang, Z., Yang, L., Ren, G., Su, S., & Zhang, C. (2022) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v20i8.24 · Cited by 1

Safety and efficacy of programmed cell death‐1 antibody SHR‐1210 combined with concurrent chemoradiotherapy to treat locally advanced esophageal squamous cell carcinoma: a study protocol for an exploratory single‐arm phase Ib trial

Wei, X., Guo, Z., Zhang, W., Zhang, T., Chen, X., Dong, J., Han, D., Lei, T., Du, Q., Pang, Q., et al. (2020) · Precision Radiation Oncology · doi:10.1002/pro6.1105

Construction of PD1/CD28 Fusion Receptor Enhances Anti-Tumor Ability of c-Met CAR-T in Gastric CancerPreprint

Chen, C., Gu, Y., Zhang, Z., Zhang, Y., He, Y.-D., Tang, F., Liu, H., & Li, Y. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3738093

The combination of Tislelizumab and apatinib obtained complete remission for alpha-fetoprotein-producing gastric cancer with microsatellite stability: case reportPreprint

Xiang, J., Wang, C., Gong, W., Liu, A., & Sun, P. (2021) · Research Square · doi:10.21203/rs.3.rs-853241/v1

Successful Conversion Surgery for Massive Hepatocellular Carcinoma with Tumor Thrombus in Main Portal Vein after Treatment with Lenvatinib Combined with Toripalimab: A Case ReportPreprint

Ouyang, J., Zhou, Y., Wang, Z., Li, Q., & Zhou, J. (2021) · Research Square · doi:10.21203/rs.3.rs-840640/v1

Clinical Outcomes of Patients with Advanced Solid Tumors of Cutaneous Capillary Hyperplasia Following Treatment with Camrelizumab: A Retrospective Case-Control Study

Wang, X., Long, Q., He, Q., Li, J., Su, Y., Jy, Z., & Li, F. (2021) · Journal of Disease Markers · doi:10.26420/jdismarkers.2021.1044

Synergistic Lethality Effects of ABT-199 and Apatinib on DLBCL: Antitumor Efficacy and Underlying MechanismsPreprint

Shi, Y., Ye, J., Shen, H., Xu, Y., Wan, R., Ye, X., Jin, J., & Xie, W. (2021) · Research Square · doi:10.21203/rs.3.rs-1013076/v1

Advances in the Application of Tumor Mutation Burden in Hepatocellular Carcinoma

张, 爱. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.123248

Application and Research Progress of Immunosuppressive Agent-Based Systemic System Therapy in Advanced Hepatocellular Carcinoma

范, 晨. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.124444

Phase 1 trial of apatinib combined with intensity-modulated radiotherapy in unresectable hepatocellular carcinomaPreprint

Wang, H., Zhu, X., Zhao, Y., Dong, D., Li, L., Cai, Y., Li, Y., & Wang, W. (2021) · Research Square · doi:10.21203/rs.3.rs-693651/v1

Gastric Cancer Secreted miR-214-3p Inhibits the Anti-Angiogenesis Effect of Apatinib by Suppressing Ferroptosis in Vascular Endothelial Cells.Preprint

Ba, Y., wang, T., Yang, C., Wang, W., Zhang, Y., Zhu, Q., & Zhang, H. (2022) · Research Square · doi:10.21203/rs.3.rs-1963577/v1

Emerging Immunotherapy: Liver Cancer Microenvironment for Treatment

Liu, S. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.106021

A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE)

Gumbleton, M., Allan, S., Conway, H., Boucher, K. M., Marvin, J., Hawks, J., Burnett, W. J., Brocklin, M. W. V., Whisenant, J. R., Gilcrease, G. W., et al. (2023) · BMC Research Notes · doi:10.1186/s13104-023-06283-5

Portal vein tumor thrombus radiotherapy improves the outcomes of immunotherapy plus bevacizumab in hepatocellular carcinoma: A multicenter real-world research of southwest ChinaPreprint

Tang, C., He, Q., Feng, J., Liao, Z., Yunli, P. E. N. G., & Gao, J. X. (2023) · Research Square · doi:10.21203/rs.3.rs-2604867/v1

Supplementary Table from Serum Concentration of CD137 and Tumor Infiltration by M1 Macrophages Predict the Response to Sintilimab plus Bevacizumab Biosimilar in Advanced Hepatocellular Carcinoma Patients

Zhang, W., Gong, C., Peng, X., Bi, X., Sun, Y., Zhou, J., Wu, F., Zeng, H., Wang, Y., Zhou, H., et al. (2023) · doi:10.1158/1078-0432.22487621.v1

Data from Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial

Xu, J., Shen, J., Gu, S., Zhang, Y., Wu, L., Wu, J., Shao, G., Zhang, Y., Xu, L., Yin, T., et al. (2023) · doi:10.1158/1078-0432.c.6530222

Data from Camrelizumab plus Famitinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket Study

Qu, Y.-Y., Zhang, H., Guo, H., Luo, H., Zou, Q., Xing, N., Xia, S., Sun, Z., Zhang, X., He, C., et al. (2023) · doi:10.1158/1078-0432.c.6530745

Data from Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial

Xu, J., Shen, J., Gu, S., Zhang, Y., Wu, L., Wu, J., Shao, G., Zhang, Y., Xu, L., Yin, T., et al. (2023) · doi:10.1158/1078-0432.c.6530222.v1

Data from Serum Concentration of CD137 and Tumor Infiltration by M1 Macrophages Predict the Response to Sintilimab plus Bevacizumab Biosimilar in Advanced Hepatocellular Carcinoma Patients

Zhang, W., Gong, C., Peng, X., Bi, X., Sun, Y., Zhou, J., Wu, F., Zeng, H., Wang, Y., Zhou, H., et al. (2023) · doi:10.1158/1078-0432.c.6532556.v1

Data from Camrelizumab plus Famitinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket Study

Qu, Y.-Y., Zhang, H., Guo, H., Luo, H., Zou, Q., Xing, N., Xia, S., Sun, Z., Zhang, X., He, C., et al. (2023) · doi:10.1158/1078-0432.c.6530745.v1

Data from Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Peng, Z. J., Jia, W. P., Wang, F., Ying, J., Deng, Y., Gu, K., Cheng, Y., Yuan, X., Xiao, J., Tai, Y., et al. (2023) · doi:10.1158/1078-0432.c.6530120.v1

Comparison of Thalidomide Versus Apatinib for Prevention of Camrelizumab-Induced Reactive Cutaneous Capillary Endothelial Proliferation

Cheng, H. D. (2023) · Journal on oncology · doi:10.52768/2692-563x/1082

Paclitaxel-based chemotherapy combined with immune checkpoint inhibitors versus chemotherapy alone as first-line treatment in HER2-negative advanced gastric cancerPreprint

Fang, Y. (2023) · doi:10.22541/au.169589529.92505705/v1

Meta-analysis of the efficacy and safety of Apatinib in the treatment of advanced gastric cancerPreprint

Yu, J., Tian, S., Li, T., & Wang, X.-Z. (2023) · Research Square · doi:10.21203/rs.3.rs-3406163/v1

Comparison of thalidomide versus apatinib for prevention of camrelizumab-induced reactive cutaneous capillary endothelial proliferation

Cheng, H. (2023) · Open Journal of Clinical and Medical Case Reports · doi:10.52768/2379-1039/2000

Disputes and Challenges of Immune Checkpoint Inhibitors in Gastrointestinal Cancers

(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4910-0

Clinical Progress of Apatinib Monotherapy or Combination with SOX Regimen and PD-1 Monoclonal Antibody in the Treatment of Advanced Gastric Cancer

刘, 晓. (2024) · Journal of Clinical Personalized Medicine · doi:10.12677/jcpm.2024.32041

Drug-eluting bead transarterial chemoembolization combined with apatinib/camrelizumab for the treatment of advanced hepatocellular carcinoma with hepatic arterioportal shunts

Ren, Y., Sun, B., Zhu, L., Chen, L., Sun, T., Dong, X., & Zheng, C. (2024) · British Journal of Radiology · doi:10.1093/bjr/tqae166

Targeted Therapies for Hepatocellular Carcinoma Treatment

Dimitroulis, D., Damaskos, C., Garmpis, N., & Garmpi, A. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1004995

Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial – Author's reply

Qin, S. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01773-2

Vasculopathy in the Correa's Cascade of Gastric Cancer: Pathological Features and Phytotherapy StrategyPreprint

Zeng, J., Ai, Y., Lu, X., Wang, H., Hu, Q., Guo, C., Zeng, Y., Ma, X., Tang, J., & Efferth, T. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.5016626

Current Research Status and Prospects of Immunotherapy Advances in Hepatocellular Carcinoma

唐, 铭. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.151037

Immunological characteristics of peripheral T cells as prognostic markers for Camrelizumab and Apatinib combination therapy in advanced squamous non-small-cell lung cancer

Wu, L., Zhi, X., Xie, S., Li, K., Chen, M., Gong, L., Wu, Q., Jiao, S., Wang, J., & Liu, T. (2025) · Molecular Immunology · doi:10.1016/j.molimm.2025.01.011

Long-term survival in a patient with ruptured advanced hepatocellular carcinoma treated with nutritional therapy combined with apatinib and camrelizumab: a case report

Liang, Y., Ruan, T., He, J., Huang, K., Wei, M., & Tan, S. (2025) · Discover Oncology · doi:10.1007/s12672-025-02099-w · Cited by 1

Molecular Targeted Therapy-Based Multimodality Treatments for Liver Cancer

Xiang, S. (2025) · Springer eBooks · doi:10.1007/978-981-97-7969-7_28

Prospects on Molecular Targeted Therapy and Immunotherapy for Liver Cancer

Dong, J., & Zhang, L. (2025) · Springer eBooks · doi:10.1007/978-981-97-7969-7_31

Case report of complete remission in two patients with Barcelona stage C hepatocellular carcinoma treated with apatinib combined with camrelizumab

Zhang, T. (2025) · American Journal of Translational Research · doi:10.62347/hwov2961

Sintilimab plus lenvatinib in combination with transarterial chemoembolization and subsequent radiofrequency ablation for unresectable hepatocellular carcinoma: a single-arm, single-center study

Chen, X., Wang, C., Yuanjie, T., Sun, H., Liu, H., Lin, C., & Yuan, Z. (2025) · Scientific Reports · doi:10.1038/s41598-025-12858-y

Development of combinatorial immunotherapy for patients with advanced gastric cancer from the perspective of immunosuppressive mechanisms in the tumor microenvironment

Mimura, K., & Kono, K. (2025) · FUKUSHIMA JOURNAL OF MEDICAL SCIENCE · doi:10.5387/fms.25-00009

Additional file 1 of Apatinib induces endoplasmic reticulum stress-mediated apoptosis and autophagy and potentiates cell sensitivity to paclitaxel via the IRE-1α–AKT–mTOR pathway in esophageal squamous cell carcinoma

Wang, Y.-M., Xu, X., Tang, J., Sun, Z.-Y., Fu, Y., Zhao, X.-J., Ma, X., & Ye, Q. (2021) · Figshare · doi:10.6084/m9.figshare.14921033

Additional file 1 of Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial

Wang, F., Qin, S., Sun, X., Ren, Z., Zhiqiang, M., Chen, Z., Chai, X., Xiong, J., Bai, Y., Yang, L., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12284675

Additional file 1 of HOXA7 promotes the metastasis of KRAS mutant colorectal cancer by regulating myeloid-derived suppressor cells

Dang, Y., Yu, J., Zhao, S., Cao, X., & Wang, Q. (2022) · Figshare · doi:10.6084/m9.figshare.19204242

Additional file 3 of A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE)

Gumbleton, M., Allan, S., Conway, H., Boucher, K. M., Marvin, J., Hawks, J., Burnett, W., Brocklin, M. W. V., Whisenant, J. R., Gilcrease, G. W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26569132

Additional file 7 of Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence

Zhang, S., Yuan, L., Danilova, L., Mo, G., Zhu, Q., Deshpande, A., Bell, A. T. F., Elisseeff, J. H., Popel, A. S., Anders, R. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26618032

Additional file 6 of Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence

Zhang, S., Yuan, L., Danilova, L., Mo, G., Zhu, Q., Deshpande, A., Bell, A. T. F., Elisseeff, J. H., Popel, A. S., Anders, R. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26618029

Additional file 8 of Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence

Zhang, S., Yuan, L., Danilova, L., Mo, G., Zhu, Q., Deshpande, A., Bell, A. T. F., Elisseeff, J. H., Popel, A. S., Anders, R. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26618035

Additional file 2 of Distinct tumour antigen-specific T-cell immune response profiles at different hepatocellular carcinoma stages

Zang, C., Zhao, Y., Qin, L., Liu, G., Sun, J., Li, K., Zhao, Y., Sheng, S., Zhang, H., He, N., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16590959

Additional file 4 of Distinct tumour antigen-specific T-cell immune response profiles at different hepatocellular carcinoma stages

Zang, C., Zhao, Y., Qin, L., Liu, G., Sun, J., Li, K., Zhao, Y., Sheng, S., Zhang, H., He, N., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16590965

Additional file 10 of Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence

Zhang, S., Yuan, L., Danilova, L., Mo, G., Zhu, Q., Deshpande, A., Bell, A. T. F., Elisseeff, J. H., Popel, A. S., Anders, R. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26618041

Additional file 4 of A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE)

Gumbleton, M., Allan, S., Conway, H., Boucher, K. M., Marvin, J., Hawks, J., Burnett, W., Brocklin, M. W. V., Whisenant, J. R., Gilcrease, G. W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26569135

Additional file 1 of Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study

Zhou, L., Wu, X., Chi, Z., Si, L., Sheng, X., Kong, Y., Mao, L., Lian, B., Tang, B., Yan, X., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19808024

Additional file 9 of Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence

Zhang, S., Yuan, L., Danilova, L., Mo, G., Zhu, Q., Deshpande, A., Bell, A. T. F., Elisseeff, J. H., Popel, A. S., Anders, R. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26618038

Additional file 2 of A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE)

Gumbleton, M., Allan, S., Conway, H., Boucher, K. M., Marvin, J., Hawks, J., Burnett, W., Brocklin, M. W. V., Whisenant, J. R., Gilcrease, G. W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26569129

Additional file 5 of A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE)

Gumbleton, M., Allan, S., Conway, H., Boucher, K. M., Marvin, J., Hawks, J., Burnett, W., Brocklin, M. W. V., Whisenant, J. R., Gilcrease, G. W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26569138

Additional file 4 of Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence

Zhang, S., Yuan, L., Danilova, L., Mo, G., Zhu, Q., Deshpande, A., Bell, A. T. F., Elisseeff, J. H., Popel, A. S., Anders, R. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26618023

Additional file 1 of A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE)

Gumbleton, M., Allan, S., Conway, H., Boucher, K. M., Marvin, J., Hawks, J., Burnett, W., Brocklin, M. W. V., Whisenant, J. R., Gilcrease, G. W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26569126

Additional file 1 of Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial

Tang, Z., Wang, Y., Yu, Y., Yuehong, C., Liang, L., Xu, C., 沈振斌, Shen, K., Wang, X., Liu, T., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19522578

Additional file 2 of Phase 1 trial of apatinib combined with intensity-modulated radiotherapy in unresectable hepatocellular carcinoma

Wang, H., 朱向高, Zhao, Y., Dong, D., Li, L., Cai, Y., Li, Y., & Wang, W. (2022) · Figshare · doi:10.6084/m9.figshare.20329389

Additional file 1 of Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets

Luo, X.-Y., Wu, K.-M., & He, X.-X. (2021) · Figshare · doi:10.6084/m9.figshare.14615275

Additional file 2 of Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial

Tang, Z., Wang, Y., Yu, Y., Yuehong, C., Liang, L., Xu, C., 沈振斌, Shen, K., Wang, X., Liu, T., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19522581

Additional file 3 of Distinct tumour antigen-specific T-cell immune response profiles at different hepatocellular carcinoma stages

Zang, C., Zhao, Y., Qin, L., Liu, G., Sun, J., Li, K., Zhao, Y., Sheng, S., Zhang, H., He, N., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16590962

Additional file 2 of Immunotherapy combined with apatinib in the treatment of advanced or metastatic gastric/gastroesophageal tumors: a systematic review and meta-analysis

Wang, J., Lin, J., Wang, R., Tong, T., & Zhao, Y. (2024) · Figshare · doi:10.6084/m9.figshare.25853195

Additional file 5 of Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence

Zhang, S., Yuan, L., Danilova, L., Mo, G., Zhu, Q., Deshpande, A., Bell, A. T. F., Elisseeff, J. H., Popel, A. S., Anders, R. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26618026

Additional file 1 of Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence

Zhang, S., Yuan, L., Danilova, L., Mo, G., Zhu, Q., Deshpande, A., Bell, A. T. F., Elisseeff, J. H., Popel, A. S., Anders, R. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26618014

Additional file 3 of Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence

Zhang, S., Yuan, L., Danilova, L., Mo, G., Zhu, Q., Deshpande, A., Bell, A. T. F., Elisseeff, J. H., Popel, A. S., Anders, R. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26618020

Additional file 2 of Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence

Zhang, S., Yuan, L., Danilova, L., Mo, G., Zhu, Q., Deshpande, A., Bell, A. T. F., Elisseeff, J. H., Popel, A. S., Anders, R. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26618017

Additional file 3 of Immunotherapy combined with apatinib in the treatment of advanced or metastatic gastric/gastroesophageal tumors: a systematic review and meta-analysis

Wang, J., Lin, J., Wang, R., Tong, T., & Zhao, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26722185

Additional file 1 of Distinct tumour antigen-specific T-cell immune response profiles at different hepatocellular carcinoma stages

Zang, C., Zhao, Y., Qin, L., Liu, G., Sun, J., Li, K., Zhao, Y., Sheng, S., Zhang, H., He, N., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16590956

Additional file 1 of Phase 1 trial of apatinib combined with intensity-modulated radiotherapy in unresectable hepatocellular carcinoma

Wang, H., 朱向高, Zhao, Y., Dong, D., Li, L., Cai, Y., Li, Y., & Wang, W. (2022) · Figshare · doi:10.6084/m9.figshare.20329386

Additional file 1 of Immunotherapy combined with apatinib in the treatment of advanced or metastatic gastric/gastroesophageal tumors: a systematic review and meta-analysis

Wang, J., Lin, J., Wang, R., Tong, T., & Zhao, Y. (2024) · Figshare · doi:10.6084/m9.figshare.25853116

Clinical Significance for Risk Stratification of Papillary Thyroid Cancer by TUMORFISHER Circulating Tumor Cell Technique

Jiang, L., Li, X., Ma, T., Zeng, P., Tan, Z., Zheng, C., Xu, J., Zhang, L., Guo, Y., Liang, J., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-2694

Efficacy and Safety of Camrelizumab Combination Therapy in Triple-Negative Breast Cancer

Akram, U., Nadeem, Z. A., Rehman, O. U., Raza, M. A., Nadeem, A., Rehman, K. A., Kareem, R., Zahid, M., Fatima, E., Ashraf, H., et al. (2026) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000001299

Identification of predictive biomarkers and dose optimization for camrelizumab combined with apatinib in the treatment of advanced hepatocellular carcinoma: a quantitative systems pharmacology approach

Huang, W., Tu, G., Li, D., Wang, C., Zhou, J., Jiao, Z., & Yang, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1617227 · Cited by 1

Lenvatinib in Combination with PD-1 Blockades as Re-Challenging Treatment for Patients with Metastatic Soft Tissue Sarcoma Following TKI Treatment Failure: A Retrospective Study

Song, G., Hu, J., He, W., Deng, C., Xu, H., Wang, A., Feng, H., Wu, H., Zhu, X., Lu, J., et al. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s587636

Conversion effects of PD-1 inhibitor camrelizumab combined with Nab-POF regimen in patients with initially unresectable locally advanced or limited metastatic gastric or gastroesophageal junction adenocarcinoma: FDZL-GC001Preprint

Guo, W., Geng, Q., Feng, W., Huang, H., Liu, Q., Yu, K., Zhao, X., Fu, H., Zhou, Y., Zhang, W., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9880362/v1

Cost-effectiveness analysis of Atezolizumab plus bevacizumab vs. Rivoceranib plus Camrelizumab as first-line treatment for unresectable hepatocellular carcinoma

Liu, M., & Liu, T. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1749414

Acquired Genetic Variants, Not Tumor Mutation Burden, Drive Resistance to Immunotherapy in Hepatocellular Carcinoma

Lee, J., Lee, H. W., Park, M. R., Shin, S., Choi, J. R., Park, H. J., Cho, K. J., Lee, S., & Park, J. Y. (2026) · Liver Cancer · doi:10.1159/000553049

Safety and efficacy of hepatic arterial infusion chemotherapy combined with camrelizumab and apatinib for advanced hepatocellular carcinoma: A retrospective clinical analysis

Ren, R., & Wang, Z. (2026) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2026.102880

Proximal Proteomics Reveals Potential Regulators of Programmed Death-Ligand 1 in Human Cancer

Shi, F., Liu, D., Liu, Y., Li, F., Zhang, C. Z., Li, Q., & Tian, Q. (2026) · ACS Omega · doi:10.1021/acsomega.6c06622

Efficacy of PD-1/PD-L1 inhibitors combined with anti-VEGF/TKIs and TACE in uHCC: a meta-analysis

Kang, X., Zhang, S., Zhang, Q., Tang, Z., Ji, J., Ni, M., & Wang, L. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1927223

Combination of Immune Checkpoint Inhibitors With Vascular Endothelial Growth Factor–Targeted Agents in Advanced Gastric and Gastroesophageal Adenocarcinoma

Akram, U., Tahira, S., Ansab, M., Zubair, M., Nisar, M., Huissain, J., & Basharat, A. (2026) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000001375

Thalidomide dose selection for prevention of camrelizumab-induced reactive cutaneous capillary endothelial proliferation: a multicenter, randomized phase II trial

Fu, X., Xu, S., Cheng, P., Lan, H., Wang, Y., Zhao, D., Liu, M., Li, S., Liu, W., Yu, G., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1917046

Anti-programmed death-1 antibody SHR-1210 (S) combined with apatinib (A) for advanced hepatocellular carcinoma (HCC), gastric cancer (GC) or esophagogastric junction (EGJ) cancer refractory to standard therapy: A phase 1 trial.

Xu, J., Zhang, Y., Jia, R., Wang, Y., Liu, R., Zhang, G., Zhao, C., Zhang, Y., Zou, J., & Wang, Q. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.4075 · Cited by 24

Anti-PD-1 antibody SHR-1210 combined with apatinib as adjuvant treatment in patients with hepatocellular carcinoma at high risk of recurrence after radical resection: Preliminary results from a multicenter, randomized, controlled phase II trial.

Zhao, H., Zhao, J., Jiang, L., Bi, X., Qian, H.-G., Du, S., Cai, J., Zhou, J., Li, Z., Liu, D., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.3_suppl.285 · Cited by 3

724P Anti-PD-1 antibody SHR-1210 combined with apatinib as adjuvant treatment in patients with hepatocellular carcinoma at high risk of recurrence after radical resection: Preliminary results from a multicenter, randomized, controlled phase II trial

Zhao, H.-Y., Du, S., Zhu, Z., Jiang, L., Che, X., Qian, H., Song, J., Liu, D., Zhang, Y., Zhang, P., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.07.848 · Cited by 2

Complete response of early stage hepatocellular carcinoma in a patient treated with combination therapy of camrelizumab (SHR-1210) and apatinib

Zhang, Z., Zhou, Y., Hu, K., Li, Z., Wang, Z., & Huang, Y. (2019) · Digestive and Liver Disease · doi:10.1016/j.dld.2019.07.005 · Cited by 9

A multicenter, randomized, controlled, phase II trial exploring adjuvant combined therapy of apatinib and SHR-1210 (anti-PD-1), in patients with hepatocellular carcinoma at high risk of recurrence after radical resection

Yan, S., Zhang, Y., Bi, X., Zhao, J., Du, S., Huang, Z., Zhang, Y., Liu, D., Li, Z., Zhou, J., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz438.022